End-of-day quote
Shanghai S.E.
06:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
6.69
CNY
|
+1.06%
|
|
+0.75%
|
-32.56%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,925
|
6,688
|
6,465
|
3,716
|
Enterprise Value (EV)
1 |
5,183
|
5,501
|
5,503
|
3,154
|
P/E ratio
|
-24.1
x
|
-25.8
x
|
-17.6
x
|
-11.3
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
149
x
|
165
x
|
76.3
x
|
32.5
x
|
EV / Revenue
|
111
x
|
136
x
|
64.9
x
|
27.6
x
|
EV / EBITDA
|
-24.9
x
|
-18.2
x
|
-14.8
x
|
-9.84
x
|
EV / FCF
|
-18.7
x
|
-11.4
x
|
-13.6
x
|
-9.18
x
|
FCF Yield
|
-5.35%
|
-8.77%
|
-7.34%
|
-10.9%
|
Price to Book
|
3.23
x
|
3.65
x
|
3.87
x
|
2.77
x
|
Nbr of stocks (in thousands)
|
359,760
|
359,760
|
374,579
|
374,579
|
Reference price
2 |
19.25
|
18.59
|
17.26
|
9.920
|
Announcement Date
|
3/30/21
|
4/29/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.911
|
20.86
|
46.62
|
40.5
|
84.74
|
114.2
|
EBITDA
1 |
-237.5
|
-171.7
|
-208.1
|
-302.7
|
-371.6
|
-320.6
|
EBIT
1 |
-261.5
|
-209.8
|
-245.6
|
-321.3
|
-398.6
|
-344.2
|
Operating Margin
|
-13,686.1%
|
-1,005.57%
|
-526.89%
|
-793.34%
|
-470.32%
|
-301.28%
|
Earnings before Tax (EBT)
1 |
-247.2
|
-195.1
|
-235.5
|
-265.3
|
-356.8
|
-329
|
Net income
1 |
-247.1
|
-192.4
|
-230.7
|
-260.1
|
-356.8
|
-329
|
Net margin
|
-12,928.22%
|
-922.58%
|
-494.89%
|
-642.07%
|
-421.01%
|
-287.93%
|
EPS
2 |
-1.023
|
-0.7266
|
-0.8000
|
-0.7200
|
-0.9800
|
-0.8800
|
Free Cash Flow
1 |
-40.59
|
-205
|
-277.1
|
-482.6
|
-403.7
|
-343.6
|
FCF margin
|
-2,124.17%
|
-982.79%
|
-594.26%
|
-1,191.59%
|
-476.36%
|
-300.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/13/20
|
8/13/20
|
3/30/21
|
4/29/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
|
5.858
|
5.67
|
20.5
|
31.49
|
27.08
|
-
|
EBITDA
|
-43.14
|
-
|
-71.4
|
-111.1
|
-
|
-
|
EBIT
|
-105.4
|
-134
|
-63.58
|
-105
|
-129.7
|
-
|
Operating Margin
|
-1,799.59%
|
-2,363.99%
|
-310.21%
|
-333.51%
|
-479.09%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
-75.71
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2300
|
-0.1600
|
-0.1800
|
-0.2900
|
-0.3500
|
-0.2000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/22
|
4/29/22
|
8/30/22
|
10/25/22
|
2/27/23
|
4/28/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
363
|
372
|
1,743
|
1,187
|
962
|
561
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-40.6
|
-205
|
-277
|
-483
|
-404
|
-344
|
ROE (net income / shareholders' equity)
|
-43.3%
|
-31.4%
|
-17.2%
|
-13.4%
|
-20.4%
|
-21.8%
|
ROA (Net income/ Total Assets)
|
-25.3%
|
-15.8%
|
-8.89%
|
-7.96%
|
-10.1%
|
-9.45%
|
Assets
1 |
974.7
|
1,221
|
2,597
|
3,269
|
3,540
|
3,479
|
Book Value Per Share
2 |
2.630
|
2.230
|
5.960
|
5.090
|
4.460
|
3.580
|
Cash Flow per Share
2 |
0.7700
|
0.8400
|
2.330
|
2.230
|
1.470
|
1.410
|
Capex
1 |
37.5
|
160
|
186
|
327
|
140
|
129
|
Capex / Sales
|
1,959.9%
|
769.41%
|
399.83%
|
807.72%
|
165.65%
|
113.22%
|
Announcement Date
|
8/13/20
|
8/13/20
|
3/30/21
|
4/29/22
|
3/30/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -32.56% | 343M | | +14.99% | 78.65B | | +9.32% | 8.94B | | -12.05% | 5.16B | | +53.66% | 4.85B | | +11.63% | 4.19B | | -23.67% | 2.32B | | +12.07% | 2.29B | | -32.35% | 2.19B | | +21.04% | 2.19B |
Specialty & Advanced Pharmaceuticals
|